| Code | Description | Claims | Beneficiaries | Total Paid |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
894,326 |
705,845 |
$43.60M |
| 8888888 |
Internal/system code - not a standard HCPCS code |
175,319 |
59,760 |
$42.78M |
| J3490 |
Unclassified drugs |
165,489 |
64,129 |
$15.85M |
| 36415 |
Collection of venous blood by venipuncture |
190,874 |
162,291 |
$13.73M |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
70,578 |
60,484 |
$6.57M |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
102,204 |
29,882 |
$6.21M |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
19,430 |
15,582 |
$4.92M |
| J0690 |
Injection, cefazolin sodium, 500 mg |
10,187 |
7,893 |
$4.74M |
| J2704 |
Injection, propofol, 10 mg |
16,344 |
11,823 |
$3.39M |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
22,441 |
18,515 |
$3.24M |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
22,337 |
19,521 |
$2.90M |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
15,494 |
13,003 |
$2.85M |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
7,161 |
6,573 |
$2.76M |
| A9270 |
Non-covered item or service |
18,962 |
7,239 |
$2.61M |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
2,786 |
2,040 |
$2.39M |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
31,557 |
22,541 |
$1.74M |
| 36416 |
|
32,018 |
25,862 |
$1.66M |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
3,751 |
3,150 |
$1.63M |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
5,566 |
4,430 |
$1.60M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
30,405 |
24,479 |
$1.38M |
| J1170 |
Injection, hydromorphone, up to 4 mg |
9,403 |
6,655 |
$1.27M |
| A0431 |
Ambulance service, conventional air services, transport, one way (rotary wing) |
493 |
389 |
$1.14M |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,871 |
4,064 |
$1.12M |
| V2020 |
Frames, purchases |
10,883 |
10,801 |
$1.04M |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
6,566 |
5,025 |
$1.03M |
| 80053 |
Comprehensive metabolic panel |
135,186 |
110,830 |
$989K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
1,048 |
964 |
$988K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
28,697 |
24,214 |
$985K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
2,092 |
1,741 |
$982K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
39,026 |
33,773 |
$871K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
3,498 |
2,942 |
$859K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,321 |
4,936 |
$823K |
| 81002 |
|
38,809 |
34,457 |
$813K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
22,656 |
21,964 |
$810K |
| 82330 |
|
13,950 |
9,533 |
$802K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
2,006 |
1,002 |
$770K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
2,018 |
1,723 |
$764K |
| 87088 |
|
24,329 |
21,295 |
$761K |
| 80305 |
|
9,921 |
7,917 |
$760K |
| J2060 |
Injection, lorazepam, 2 mg |
3,842 |
3,029 |
$744K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
2,911 |
2,235 |
$718K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
12,654 |
9,314 |
$706K |
| 71046 |
Radiologic examination, chest; 2 views |
20,498 |
18,428 |
$668K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
7,087 |
5,839 |
$629K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
6,960 |
6,300 |
$622K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
28,482 |
15,913 |
$618K |
| J1453 |
Injection, fosaprepitant, 1 mg |
791 |
493 |
$599K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
1,245 |
773 |
$578K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
980 |
943 |
$560K |
| 81025 |
|
27,094 |
24,551 |
$552K |
| A0436 |
Rotary wing air mileage, per statute mile |
488 |
387 |
$536K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
9,873 |
9,464 |
$514K |
| J1790 |
Injection, droperidol, up to 5 mg |
2,235 |
1,998 |
$512K |
| 77336 |
|
2,053 |
903 |
$502K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
18,164 |
15,496 |
$495K |
| J0475 |
Injection, baclofen, 10 mg |
2,593 |
2,292 |
$446K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
2,126 |
1,937 |
$434K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
23,275 |
21,057 |
$388K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
2,356 |
2,192 |
$377K |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
1,045 |
942 |
$371K |
| 90686 |
|
42,392 |
40,916 |
$370K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
559 |
538 |
$366K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
12,735 |
11,185 |
$346K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
4,305 |
4,117 |
$335K |
| 95811 |
|
657 |
618 |
$335K |
| J3489 |
Injection, zoledronic acid, 1 mg |
392 |
352 |
$322K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
2,241 |
2,160 |
$317K |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
4,008 |
3,174 |
$313K |
| 64615 |
|
1,382 |
1,316 |
$308K |
| 76830 |
Ultrasound, transvaginal |
3,083 |
2,945 |
$303K |
| C9399 |
Unclassified drugs or biologicals |
6,896 |
5,363 |
$300K |
| 73610 |
|
5,804 |
5,194 |
$291K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
3,863 |
3,485 |
$290K |
| 73630 |
|
7,615 |
6,838 |
$288K |
| 86850 |
|
10,109 |
8,574 |
$283K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
4,713 |
3,925 |
$283K |
| 73562 |
|
6,275 |
5,783 |
$282K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
4,604 |
4,397 |
$270K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
2,629 |
2,486 |
$267K |
| 80076 |
|
8,547 |
7,356 |
$262K |
| J1815 |
Injection, insulin, per 5 units |
3,077 |
1,563 |
$258K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,820 |
2,695 |
$253K |
| 77386 |
|
1,370 |
130 |
$247K |
| 83986 |
|
2,758 |
2,005 |
$245K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
2,026 |
1,258 |
$242K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
3,609 |
3,513 |
$238K |
| 87081 |
|
3,987 |
3,818 |
$238K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
3,065 |
2,406 |
$236K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
1,400 |
786 |
$234K |
| 0001A |
|
11,626 |
7,927 |
$233K |
| 87653 |
|
3,046 |
2,940 |
$227K |
| 87480 |
|
5,550 |
5,215 |
$226K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
7,895 |
7,255 |
$222K |
| 73030 |
|
5,708 |
5,173 |
$219K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
3,020 |
2,851 |
$217K |
| 87070 |
|
5,738 |
4,747 |
$210K |
| A9152 |
Single vitamin/mineral/trace element, oral, per dose, not otherwise specified |
1,549 |
694 |
$210K |
| 73110 |
|
4,640 |
3,966 |
$208K |
| 97161 |
|
3,709 |
3,581 |
$198K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
33,143 |
24,642 |
$198K |
| 59025 |
Fetal non-stress test |
7,107 |
3,627 |
$191K |
| 73130 |
|
5,479 |
4,880 |
$191K |
| 99173 |
|
8,642 |
8,398 |
$180K |
| 72141 |
|
1,368 |
1,292 |
$179K |
| 72100 |
|
4,964 |
4,537 |
$177K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
37,256 |
29,698 |
$176K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,253 |
1,183 |
$175K |
| 72110 |
|
2,942 |
2,801 |
$174K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
127 |
95 |
$169K |
| A9153 |
Multiple vitamins, with or without minerals and trace elements, oral, per dose, not otherwise specified |
1,287 |
779 |
$162K |
| A6257 |
Transparent film, sterile, 16 sq. in. or less, each dressing |
6,209 |
5,087 |
$160K |
| 95885 |
|
871 |
822 |
$158K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
5,057 |
4,825 |
$157K |
| 76801 |
|
3,043 |
2,615 |
$156K |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
3,253 |
2,940 |
$153K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
2,026 |
1,887 |
$151K |
| 95886 |
|
1,056 |
1,012 |
$149K |
| 97162 |
|
2,963 |
2,821 |
$147K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,112 |
4,871 |
$144K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
462 |
375 |
$142K |
| 77300 |
|
442 |
386 |
$141K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
265 |
238 |
$134K |
| J1630 |
Injection, haloperidol, up to 5 mg |
2,098 |
1,769 |
$129K |
| 73560 |
|
4,213 |
3,602 |
$128K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
13,443 |
7,569 |
$128K |
| 94010 |
|
2,756 |
2,495 |
$125K |
| 73140 |
|
2,093 |
1,893 |
$125K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
193 |
175 |
$124K |
| 64642 |
|
275 |
243 |
$123K |
| 70450 |
Computed tomography, head or brain; without contrast material |
5,619 |
4,997 |
$121K |
| J0572 |
Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine |
508 |
431 |
$121K |
| 73502 |
|
3,588 |
3,285 |
$120K |
| 17110 |
|
2,245 |
2,021 |
$120K |
| 72040 |
|
2,465 |
2,258 |
$118K |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
390 |
359 |
$118K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
765 |
736 |
$116K |
| 72050 |
|
1,741 |
1,649 |
$115K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
13,740 |
11,935 |
$113K |
| 77334 |
|
897 |
585 |
$111K |
| 81001 |
|
45,102 |
38,190 |
$111K |
| 77062 |
|
1,138 |
1,106 |
$111K |
| G0008 |
Administration of influenza virus vaccine |
52,904 |
50,956 |
$109K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
2,768 |
1,379 |
$108K |
| 87631 |
|
936 |
906 |
$107K |
| 87077 |
|
4,276 |
3,769 |
$105K |
| 31231 |
|
1,926 |
1,795 |
$104K |
| 94060 |
|
885 |
835 |
$102K |
| 82962 |
|
25,206 |
15,015 |
$101K |
| 77412 |
|
1,541 |
212 |
$100K |
| 0002A |
|
4,078 |
3,115 |
$98K |
| 71250 |
|
1,992 |
1,841 |
$97K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
211 |
198 |
$97K |
| J0574 |
Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine |
423 |
362 |
$94K |
| 73080 |
|
1,596 |
1,472 |
$91K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
206 |
115 |
$91K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
457 |
416 |
$90K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,702 |
1,553 |
$89K |
| 93356 |
|
597 |
559 |
$84K |
| 83013 |
|
2,330 |
2,247 |
$84K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
45,397 |
35,064 |
$82K |
| J1756 |
Injection, iron sucrose, 1 mg |
1,604 |
825 |
$81K |
| 76376 |
|
652 |
619 |
$81K |
| 69210 |
|
1,684 |
1,582 |
$79K |
| 74018 |
|
2,804 |
2,474 |
$78K |
| 76536 |
|
1,251 |
1,195 |
$78K |
| 77080 |
|
919 |
877 |
$77K |
| 85610 |
|
27,748 |
19,345 |
$77K |
| J0178 |
Injection, aflibercept, 1 mg |
1,590 |
1,299 |
$73K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
4,985 |
4,812 |
$72K |
| 90651 |
|
8,020 |
7,866 |
$72K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
24,933 |
20,330 |
$71K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
152,007 |
121,506 |
$69K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
3,395 |
2,926 |
$69K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
4,401 |
2,687 |
$67K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
4,431 |
3,977 |
$67K |
| 73590 |
|
2,152 |
1,891 |
$66K |
| 76770 |
|
1,385 |
1,267 |
$65K |
| 90648 |
|
16,480 |
16,227 |
$64K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
3,621 |
2,215 |
$64K |
| 72072 |
|
1,778 |
1,625 |
$64K |
| 93321 |
|
2,250 |
2,042 |
$63K |
| 72082 |
|
1,308 |
1,204 |
$62K |
| 88142 |
|
7,107 |
6,805 |
$60K |
| 73221 |
|
469 |
448 |
$60K |
| 91200 |
|
1,048 |
1,001 |
$60K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
10,247 |
9,307 |
$60K |
| 93971 |
|
2,682 |
2,406 |
$60K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
22,195 |
16,321 |
$60K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,184 |
1,022 |
$58K |
| 87340 |
|
10,180 |
9,483 |
$55K |
| 71045 |
Radiologic examination, chest; single view |
9,492 |
8,130 |
$55K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
659 |
615 |
$54K |
| 90633 |
|
8,505 |
8,385 |
$53K |
| 92557 |
|
1,644 |
1,553 |
$53K |
| 0053A |
|
2,398 |
2,184 |
$53K |
| 70486 |
|
1,169 |
1,101 |
$52K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
2,070 |
1,894 |
$51K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
200 |
176 |
$51K |
| 76642 |
|
2,020 |
1,758 |
$50K |
| 73090 |
|
1,498 |
1,363 |
$49K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
9,233 |
5,607 |
$49K |
| 96402 |
|
516 |
444 |
$48K |
| 77280 |
|
94 |
79 |
$47K |
| 92083 |
|
2,818 |
2,576 |
$47K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
993 |
988 |
$47K |
| J1250 |
Injection, dobutamine hydrochloride, per 250 mg |
356 |
322 |
$47K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
20,542 |
16,009 |
$47K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
9,366 |
8,575 |
$44K |
| J1071 |
Injection, testosterone cypionate, 1 mg |
949 |
535 |
$43K |
| 87210 |
|
3,572 |
3,183 |
$43K |
| 77295 |
|
29 |
27 |
$43K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
7,498 |
5,303 |
$42K |
| 95806 |
|
453 |
443 |
$40K |
| 77290 |
|
104 |
88 |
$40K |
| 0071A |
|
1,404 |
1,229 |
$39K |
| T1015 |
Clinic visit/encounter, all-inclusive |
4,035 |
1,736 |
$39K |
| 88304 |
|
867 |
769 |
$39K |
| 69209 |
|
788 |
734 |
$39K |
| 97165 |
|
651 |
612 |
$39K |
| J3480 |
Injection, potassium chloride, per 2 meq |
625 |
421 |
$39K |
| 0003A |
|
1,631 |
1,445 |
$38K |
| 82043 |
|
7,407 |
6,921 |
$37K |
| 73600 |
|
677 |
622 |
$36K |
| 77301 |
|
52 |
50 |
$36K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
29,919 |
29,196 |
$36K |
| 74019 |
|
1,362 |
1,239 |
$35K |
| V2103 |
Spherocylinder, single vision, plano to plus or minus 4.00d sphere, .12 to 2.00d cylinder, per lens |
6,041 |
5,991 |
$35K |
| 86832 |
|
442 |
375 |
$35K |
| 82274 |
|
1,093 |
1,057 |
$34K |
| 76882 |
|
1,002 |
934 |
$34K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
3,844 |
3,135 |
$34K |
| J3411 |
Injection, thiamine hcl, 100 mg |
489 |
309 |
$34K |
| 73564 |
|
543 |
526 |
$33K |
| 20610 |
|
4,744 |
4,165 |
$32K |
| 12001 |
|
921 |
893 |
$32K |
| 82565 |
|
7,453 |
6,805 |
$32K |
| 71101 |
|
629 |
583 |
$32K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
639 |
524 |
$31K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
60,130 |
49,887 |
$31K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
515 |
176 |
$30K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
565 |
473 |
$30K |
| 31575 |
|
827 |
761 |
$29K |
| 0072A |
|
820 |
812 |
$29K |
| 73552 |
|
1,181 |
1,042 |
$29K |
| 11981 |
|
673 |
648 |
$29K |
| 92558 |
|
348 |
342 |
$28K |
| 73660 |
|
534 |
502 |
$28K |
| 20611 |
|
2,202 |
1,957 |
$27K |
| 83993 |
|
784 |
754 |
$27K |
| 90685 |
|
3,001 |
2,974 |
$27K |
| 92136 |
|
974 |
869 |
$27K |
| G0009 |
Administration of pneumococcal vaccine |
22,706 |
21,993 |
$27K |
| 92550 |
|
511 |
480 |
$27K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,405 |
1,283 |
$27K |
| 17000 |
|
860 |
762 |
$26K |
| 95812 |
|
167 |
154 |
$26K |
| 10060 |
|
1,355 |
1,255 |
$26K |
| 93970 |
|
519 |
475 |
$26K |
| J0897 |
Injection, denosumab, 1 mg |
66 |
52 |
$26K |
| 97163 |
|
400 |
390 |
$26K |
| 91320 |
|
474 |
469 |
$26K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
3,487 |
3,333 |
$25K |
| 93308 |
|
1,367 |
1,225 |
$25K |
| 93296 |
|
1,441 |
1,320 |
$25K |
| 90688 |
|
5,024 |
4,775 |
$25K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
927 |
847 |
$25K |
| 90715 |
|
12,922 |
12,455 |
$25K |
| 84156 |
|
6,899 |
5,882 |
$25K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
39 |
37 |
$24K |
| 97116 |
|
1,604 |
752 |
$24K |
| 51798 |
|
4,397 |
3,678 |
$24K |
| 97166 |
|
481 |
451 |
$24K |
| J1644 |
Injection, heparin sodium, per 1000 units |
3,836 |
1,994 |
$24K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
2,607 |
2,431 |
$23K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
1,792 |
1,112 |
$23K |
| A0430 |
Ambulance service, conventional air services, transport, one way (fixed wing) |
22 |
15 |
$22K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
4,670 |
4,326 |
$22K |
| 87045 |
|
695 |
667 |
$22K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
66,210 |
61,457 |
$22K |
| 72170 |
|
1,472 |
1,236 |
$21K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
36,399 |
27,440 |
$21K |
| 76000 |
|
1,874 |
1,616 |
$21K |
| 0052A |
|
800 |
755 |
$20K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
7,846 |
6,463 |
$20K |
| 93923 |
|
427 |
395 |
$20K |
| A0435 |
Fixed wing air mileage, per statute mile |
22 |
15 |
$20K |
| 51705 |
|
754 |
673 |
$20K |
| 93017 |
|
626 |
561 |
$20K |
| 96158 |
|
691 |
464 |
$20K |
| 78264 |
|
79 |
77 |
$19K |
| 82731 |
|
142 |
130 |
$19K |
| 0054A |
|
1,064 |
982 |
$19K |
| 76870 |
|
366 |
347 |
$19K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
132 |
108 |
$18K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,634 |
1,453 |
$17K |
| 84484 |
|
14,830 |
11,001 |
$17K |
| 73521 |
|
419 |
403 |
$17K |
| 80061 |
Lipid panel |
34,911 |
32,866 |
$17K |
| 73070 |
|
753 |
656 |
$17K |
| 87040 |
|
3,779 |
1,896 |
$16K |
| V2784 |
Lens, polycarbonate or equal, any index, per lens |
3,874 |
3,841 |
$16K |
| 73000 |
|
280 |
253 |
$16K |
| 90670 |
|
17,792 |
17,357 |
$16K |
| 88720 |
|
518 |
369 |
$15K |
| 99188 |
|
683 |
650 |
$15K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
518 |
468 |
$15K |
| 88184 |
|
1,028 |
799 |
$15K |
| 82805 |
|
13,670 |
9,455 |
$15K |
| J7050 |
Infusion, normal saline solution, 250 cc |
738 |
372 |
$15K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
6,129 |
4,155 |
$15K |
| 92134 |
|
6,522 |
5,871 |
$15K |
| 82728 |
|
19,022 |
17,817 |
$15K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
3,790 |
3,012 |
$14K |
| A4344 |
Indwelling catheter, foley type, two-way, all silicone or polyurethane, each |
121 |
110 |
$14K |
| 90480 |
|
841 |
836 |
$14K |
| Q3014 |
Telehealth originating site facility fee |
11,671 |
8,262 |
$14K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
1,467 |
978 |
$14K |
| 90696 |
|
3,496 |
3,442 |
$14K |
| 99201 |
|
1,356 |
1,298 |
$14K |
| 87632 |
|
266 |
256 |
$14K |
| 86900 |
|
10,986 |
9,078 |
$14K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
416 |
171 |
$14K |
| 77061 |
|
172 |
170 |
$14K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
20,275 |
19,082 |
$13K |
| 86769 |
|
474 |
441 |
$13K |
| 0051A |
|
644 |
596 |
$13K |
| 87507 |
|
407 |
396 |
$13K |
| 86592 |
|
11,838 |
11,220 |
$13K |
| 72146 |
|
111 |
104 |
$13K |
| 54150 |
|
377 |
359 |
$13K |
| 52000 |
|
500 |
464 |
$13K |
| 93325 |
|
2,355 |
2,139 |
$12K |
| 73700 |
|
200 |
185 |
$12K |
| 84132 |
|
12,996 |
9,333 |
$12K |
| J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg |
1,169 |
373 |
$12K |
| 85651 |
|
11,323 |
10,250 |
$12K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
5,386 |
4,913 |
$12K |
| 76942 |
|
2,426 |
2,119 |
$12K |
| J9271 |
Injection, pembrolizumab, 1 mg |
220 |
179 |
$12K |
| 11976 |
|
82 |
81 |
$12K |
| 83550 |
|
10,746 |
10,066 |
$11K |
| 73060 |
|
535 |
450 |
$11K |
| J1940 |
Injection, furosemide, up to 20 mg |
46 |
38 |
$11K |
| 84702 |
|
4,391 |
3,258 |
$11K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
3,613 |
3,099 |
$11K |
| 84443 |
Thyroid stimulating hormone (TSH) |
49,815 |
46,214 |
$11K |
| 97535 |
Self-care/home management training, each 15 minutes |
769 |
479 |
$11K |
| 92250 |
|
1,655 |
1,504 |
$10K |
| 88307 |
|
1,305 |
1,065 |
$10K |
| 88342 |
|
2,590 |
2,232 |
$10K |
| 76937 |
|
5,121 |
4,153 |
$10K |
| 90677 |
|
2,024 |
2,008 |
$10K |
| 83540 |
|
12,779 |
11,962 |
$10K |
| 20553 |
|
1,096 |
938 |
$10K |
| J3360 |
Injection, diazepam, up to 5 mg |
79 |
68 |
$10K |
| 31720 |
|
182 |
167 |
$10K |
| 96159 |
|
618 |
401 |
$10K |
| 96401 |
|
18 |
12 |
$9K |
| 90750 |
|
65 |
64 |
$9K |
| 85027 |
|
22,682 |
19,127 |
$9K |
| 58301 |
|
775 |
746 |
$9K |
| 90732 |
|
3,481 |
3,222 |
$9K |
| 80069 |
|
4,838 |
4,108 |
$9K |
| 96367 |
|
2,237 |
1,564 |
$9K |
| 58300 |
|
1,610 |
1,538 |
$9K |
| 87338 |
|
660 |
645 |
$9K |
| 77077 |
|
1,151 |
1,096 |
$9K |
| A4565 |
Slings |
229 |
200 |
$9K |
| 11721 |
|
769 |
685 |
$9K |
| 82247 |
|
2,175 |
1,349 |
$9K |
| 82570 |
|
8,089 |
7,519 |
$9K |
| 92552 |
|
117 |
117 |
$9K |
| 87205 |
|
5,799 |
4,703 |
$9K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
112 |
110 |
$8K |
| 74183 |
|
644 |
605 |
$8K |
| 92133 |
|
2,841 |
2,572 |
$8K |
| 0073A |
|
224 |
222 |
$8K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
556 |
513 |
$8K |
| G0378 |
Hospital observation service, per hour |
5,527 |
4,079 |
$8K |
| 64643 |
|
92 |
82 |
$8K |
| 16020 |
|
885 |
619 |
$8K |
| 80164 |
|
2,075 |
1,849 |
$8K |
| 71271 |
|
108 |
106 |
$8K |
| 62370 |
|
1,875 |
1,672 |
$8K |
| 72131 |
|
324 |
292 |
$7K |
| 80050 |
General health panel |
2,343 |
2,249 |
$7K |
| 0399T |
|
81 |
70 |
$7K |
| 90734 |
|
5,670 |
5,556 |
$7K |
| 86480 |
|
2,914 |
2,770 |
$7K |
| J0485 |
Injection, belatacept, 1 mg |
197 |
64 |
$7K |
| 86140 |
|
13,898 |
12,414 |
$7K |
| 81015 |
|
1,587 |
1,501 |
$7K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
4,098 |
3,815 |
$7K |
| V2104 |
Spherocylinder, single vision, plano to plus or minus 4.00d sphere, 2.12 to 4.00d cylinder, per lens |
2,040 |
2,027 |
$6K |
| 80178 |
|
3,553 |
3,177 |
$6K |
| 82670 |
|
2,024 |
1,913 |
$6K |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
214 |
207 |
$6K |
| 87186 |
|
10,931 |
9,858 |
$6K |
| 87536 |
|
5,269 |
4,976 |
$6K |
| 87324 |
|
841 |
799 |
$6K |
| 94760 |
|
118 |
113 |
$6K |
| 93297 |
|
208 |
200 |
$6K |
| 82550 |
|
3,026 |
2,582 |
$5K |
| 83735 |
|
15,327 |
10,013 |
$5K |
| 90707 |
|
3,937 |
3,867 |
$5K |
| 87147 |
|
4,943 |
4,526 |
$5K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
279 |
265 |
$5K |
| 86833 |
|
387 |
330 |
$5K |
| 87102 |
|
747 |
569 |
$5K |
| 92551 |
|
72 |
70 |
$5K |
| 90656 |
|
2,091 |
2,089 |
$5K |
| 90680 |
|
11,225 |
11,059 |
$5K |
| 87799 |
|
1,449 |
878 |
$5K |
| 51703 |
|
336 |
281 |
$5K |
| 12011 |
|
174 |
169 |
$5K |
| 82607 |
|
16,023 |
14,811 |
$5K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
174 |
133 |
$5K |
| 86235 |
|
1,737 |
1,402 |
$5K |
| A9698 |
Non-radioactive contrast imaging material, not otherwise classified, per study |
869 |
702 |
$5K |
| 90700 |
|
3,907 |
3,838 |
$5K |
| 85379 |
|
4,050 |
3,687 |
$5K |
| 52310 |
|
52 |
50 |
$5K |
| 93270 |
|
735 |
711 |
$5K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
39,173 |
37,808 |
$5K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
3,168 |
2,929 |
$5K |
| 87529 |
|
313 |
278 |
$4K |
| 88173 |
|
70 |
65 |
$4K |
| 93225 |
|
304 |
271 |
$4K |
| 82784 |
|
4,860 |
4,244 |
$4K |
| 83690 |
|
12,889 |
11,129 |
$4K |
| 70491 |
|
961 |
892 |
$4K |
| 87497 |
|
1,881 |
942 |
$4K |
| 83516 |
|
5,141 |
3,960 |
$4K |
| 90716 |
|
3,835 |
3,768 |
$4K |
| 80197 |
|
4,753 |
2,391 |
$4K |
| 86803 |
|
15,938 |
15,278 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
34,475 |
30,373 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
17,036 |
16,322 |
$4K |
| 93660 |
|
14 |
12 |
$4K |
| 73650 |
|
83 |
77 |
$4K |
| 94762 |
|
45 |
41 |
$4K |
| V2100 |
Sphere, single vision, plano to plus or minus 4.00, per lens |
2,511 |
2,490 |
$4K |
| 87177 |
|
249 |
225 |
$4K |
| 29125 |
|
364 |
350 |
$4K |
| 87075 |
|
1,473 |
1,087 |
$4K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
5,521 |
3,763 |
$4K |
| 84100 |
|
9,554 |
6,194 |
$4K |
| 82040 |
|
826 |
785 |
$4K |
| 86304 |
|
1,073 |
880 |
$4K |
| 81513 |
|
4,397 |
4,207 |
$4K |
| 83880 |
|
6,346 |
5,523 |
$4K |
| 96376 |
|
8,990 |
6,110 |
$4K |
| 97542 |
|
58 |
51 |
$4K |
| 76510 |
|
40 |
38 |
$4K |
| 83655 |
|
2,143 |
2,090 |
$3K |
| 72220 |
|
90 |
88 |
$3K |
| 66982 |
|
264 |
228 |
$3K |
| 84439 |
|
10,258 |
9,529 |
$3K |
| 83520 |
|
1,760 |
1,565 |
$3K |
| 82340 |
|
60 |
54 |
$3K |
| 87015 |
|
22 |
15 |
$3K |
| 82103 |
|
261 |
237 |
$3K |
| 90636 |
|
520 |
490 |
$3K |
| 86901 |
|
10,993 |
9,072 |
$3K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
1,453 |
1,063 |
$3K |
| 83615 |
|
8,660 |
5,647 |
$3K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
1,007 |
870 |
$3K |
| 85018 |
|
3,320 |
2,982 |
$3K |
| 86317 |
|
3,473 |
3,166 |
$3K |
| 82653 |
|
26 |
26 |
$3K |
| 0031A |
|
449 |
412 |
$3K |
| 97763 |
|
67 |
58 |
$3K |
| 73620 |
|
276 |
250 |
$3K |
| 83605 |
|
4,337 |
3,306 |
$3K |
| 84165 |
|
2,525 |
2,223 |
$3K |
| 92567 |
|
944 |
889 |
$3K |
| 95813 |
|
12 |
12 |
$3K |
| 11100 |
|
268 |
235 |
$3K |
| 82378 |
|
2,030 |
1,639 |
$3K |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
626 |
567 |
$3K |
| 85007 |
|
1,332 |
615 |
$3K |
| 94761 |
|
101 |
90 |
$3K |
| 70496 |
|
1,131 |
1,038 |
$3K |
| 11720 |
|
449 |
395 |
$3K |
| 84703 |
|
2,141 |
1,944 |
$2K |
| 11750 |
|
54 |
39 |
$2K |
| 90710 |
|
4,115 |
4,065 |
$2K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
604 |
557 |
$2K |
| 94727 |
|
2,662 |
2,482 |
$2K |
| 87522 |
Neg quan hep c or qual rna |
3,363 |
3,069 |
$2K |
| C1729 |
Catheter, drainage |
705 |
524 |
$2K |
| 80156 |
|
231 |
205 |
$2K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
4,458 |
756 |
$2K |
| 85045 |
|
1,138 |
884 |
$2K |
| 84153 |
|
3,162 |
2,922 |
$2K |
| 36000 |
|
3,655 |
2,923 |
$2K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
8,402 |
7,731 |
$2K |
| 82310 |
|
1,307 |
1,155 |
$2K |
| 81511 |
|
819 |
784 |
$2K |
| 82533 |
|
833 |
721 |
$2K |
| 66821 |
|
16 |
14 |
$2K |
| 93976 |
|
517 |
484 |
$2K |
| 86923 |
|
1,179 |
838 |
$2K |
| 87493 |
|
389 |
365 |
$2K |
| C1769 |
Guide wire |
2,995 |
2,426 |
$2K |
| 70498 |
|
979 |
905 |
$2K |
| 36430 |
|
809 |
502 |
$2K |
| 99153 |
Mod sedat endo service >5yrs |
7,173 |
6,443 |
$2K |
| 99152 |
|
5,901 |
5,420 |
$2K |
| 46600 |
|
167 |
165 |
$2K |
| 82105 |
|
2,500 |
2,270 |
$2K |
| 0082A |
|
375 |
322 |
$2K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
29 |
27 |
$2K |
| 86003 |
|
344 |
301 |
$2K |
| 64493 |
|
700 |
594 |
$2K |
| 96152 |
|
50 |
38 |
$2K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
1,879 |
1,617 |
$2K |
| C8930 |
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision |
152 |
139 |
$2K |
| 90713 |
|
614 |
603 |
$2K |
| 86334 |
|
1,937 |
1,666 |
$2K |
| 92025 |
|
85 |
79 |
$2K |
| 64483 |
|
1,442 |
1,342 |
$2K |
| 90687 |
|
526 |
518 |
$2K |
| 43235 |
|
890 |
840 |
$2K |
| 86361 |
|
3,127 |
2,992 |
$2K |
| 77066 |
Tomosynthesis, mammo |
1,243 |
1,165 |
$2K |
| 11104 |
|
531 |
500 |
$2K |
| 64450 |
|
727 |
627 |
$2K |
| 80177 |
|
475 |
441 |
$2K |
| 95117 |
|
637 |
336 |
$2K |
| 11730 |
|
27 |
26 |
$2K |
| 88185 |
|
1,368 |
810 |
$2K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
586 |
532 |
$2K |
| 90723 |
|
12,882 |
12,676 |
$2K |
| 86160 |
|
1,634 |
1,459 |
$2K |
| Q9961 |
High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml |
264 |
232 |
$2K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
208 |
183 |
$2K |
| 77081 |
|
471 |
454 |
$2K |
| 86706 |
|
986 |
953 |
$2K |
| 83970 |
|
4,580 |
4,207 |
$1K |
| 97802 |
|
1,112 |
1,087 |
$1K |
| 82948 |
|
180 |
152 |
$1K |
| 96156 |
|
51 |
44 |
$1K |
| 77065 |
Tomosynthesis, mammo |
295 |
279 |
$1K |
| Q0114 |
Fern test |
1,991 |
1,737 |
$1K |
| 86038 |
|
3,208 |
3,045 |
$1K |
| 29130 |
|
98 |
94 |
$1K |
| 84295 |
|
12,823 |
9,231 |
$1K |
| A4648 |
Tissue marker, implantable, any type, each |
16 |
14 |
$1K |
| 80143 |
|
2,281 |
2,067 |
$1K |
| 97803 |
|
1,305 |
1,221 |
$1K |
| 82950 |
|
3,171 |
3,073 |
$1K |
| 82977 |
|
2,791 |
2,032 |
$1K |
| 77002 |
|
468 |
428 |
$1K |
| 96415 |
|
3,537 |
2,495 |
$1K |
| 76881 |
|
15 |
13 |
$1K |
| 84160 |
|
632 |
544 |
$1K |
| 80074 |
|
1,200 |
1,131 |
$1K |
| 95970 |
|
315 |
279 |
$1K |
| 84134 |
|
2,002 |
1,790 |
$1K |
| 94729 |
|
2,686 |
2,504 |
$1K |
| 11102 |
|
681 |
638 |
$1K |
| 51700 |
|
136 |
85 |
$1K |
| 96416 |
|
448 |
261 |
$1K |
| 82746 |
|
7,429 |
6,989 |
$1K |
| 86922 |
|
119 |
75 |
$1K |
| 82785 |
|
540 |
511 |
$1K |
| 92285 |
|
617 |
587 |
$1K |
| 93351 |
|
727 |
688 |
$1K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
14 |
13 |
$1K |
| 93990 |
|
276 |
223 |
$1K |
| 72128 |
|
121 |
115 |
$978.70 |
| 12002 |
|
99 |
94 |
$945.52 |
| 90744 |
|
423 |
414 |
$944.30 |
| 85014 |
|
1,660 |
1,475 |
$940.15 |
| 82077 |
|
2,763 |
2,463 |
$935.40 |
| 96164 |
|
97 |
37 |
$925.48 |
| 74178 |
|
190 |
176 |
$920.15 |
| L4360 |
Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
15 |
14 |
$916.38 |
| 86703 |
|
540 |
484 |
$902.58 |
| 82525 |
|
1,608 |
1,523 |
$902.20 |
| 88313 |
|
492 |
404 |
$899.10 |
| 72156 |
|
611 |
575 |
$886.95 |
| 95910 |
|
112 |
110 |
$876.08 |
| 11719 |
|
79 |
77 |
$871.54 |
| 88240 |
|
1,112 |
958 |
$853.02 |
| 86255 |
|
440 |
400 |
$849.12 |
| 84403 |
|
4,420 |
4,104 |
$842.31 |
| 0081A |
|
760 |
682 |
$826.67 |
| 85730 |
|
6,098 |
5,235 |
$825.49 |
| J7507 |
Tacrolimus, immediate release, oral, 1 mg |
38 |
13 |
$825.41 |
| 83883 |
|
553 |
440 |
$816.24 |
| 83861 |
|
1,827 |
1,679 |
$812.78 |
| 86765 |
|
547 |
510 |
$811.03 |
| 84146 |
|
2,299 |
2,175 |
$786.79 |
| 86704 |
|
2,747 |
2,607 |
$780.32 |
| 49083 |
|
30 |
13 |
$775.80 |
| 74160 |
|
48 |
42 |
$744.43 |
| 90662 |
|
470 |
390 |
$696.72 |
| 94618 |
|
40 |
37 |
$690.13 |
| 89051 |
|
1,357 |
1,023 |
$672.55 |
| 93288 |
|
26 |
24 |
$661.76 |
| 86300 |
|
352 |
300 |
$651.03 |
| 84270 |
|
2,253 |
2,065 |
$639.02 |
| 90739 |
|
118 |
110 |
$612.66 |
| 51741 |
|
819 |
760 |
$611.36 |
| 84550 |
|
3,048 |
2,665 |
$600.28 |
| 94660 |
|
142 |
115 |
$583.71 |
| 87305 |
|
212 |
102 |
$549.87 |
| 58100 |
|
109 |
104 |
$549.45 |
| 95911 |
|
55 |
53 |
$546.66 |
| J7325 |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
18 |
12 |
$540.83 |
| 74230 |
|
84 |
73 |
$529.50 |
| 86141 |
|
2,178 |
1,970 |
$518.81 |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
259 |
221 |
$518.51 |
| 38222 |
|
42 |
38 |
$518.22 |
| 90694 |
|
580 |
530 |
$514.97 |
| 86200 |
|
1,912 |
1,808 |
$509.51 |
| 95908 |
|
105 |
102 |
$506.39 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
292 |
221 |
$504.96 |
| 90746 |
|
50 |
46 |
$500.38 |
| 73200 |
|
14 |
12 |
$499.96 |
| 86762 |
|
3,983 |
3,757 |
$498.15 |
| 93242 |
|
73 |
70 |
$477.86 |
| J2785 |
Injection, regadenoson, 0.1 mg |
266 |
237 |
$467.50 |
| 86256 |
|
753 |
712 |
$464.09 |
| 87427 |
|
765 |
730 |
$460.42 |
| 86308 |
|
69 |
69 |
$450.35 |
| 87481 |
|
4,306 |
4,140 |
$448.05 |
| 72080 |
|
13 |
13 |
$447.32 |
| 83001 |
|
2,269 |
2,164 |
$445.40 |
| 87449 |
|
939 |
841 |
$445.28 |
| 64447 |
|
206 |
177 |
$442.75 |
| 87902 |
|
539 |
471 |
$432.47 |
| 86580 |
|
13 |
12 |
$420.61 |
| 36591 |
|
4,434 |
2,826 |
$417.02 |
| 94799 |
|
99 |
53 |
$408.16 |
| 86376 |
|
967 |
926 |
$407.29 |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,562 |
1,425 |
$404.50 |
| 86039 |
|
1,469 |
1,229 |
$402.99 |
| 82150 |
|
1,050 |
850 |
$400.62 |
| 88341 |
|
61 |
51 |
$398.99 |
| 84425 |
|
1,960 |
1,875 |
$396.13 |
| 93280 |
|
142 |
121 |
$383.62 |
| 87660 |
|
5,559 |
5,222 |
$379.11 |
| 96165 |
|
98 |
37 |
$366.38 |
| 86309 |
|
157 |
146 |
$362.80 |
| 92553 |
|
12 |
12 |
$358.75 |
| 82384 |
|
45 |
27 |
$358.23 |
| J2280 |
Injection, moxifloxacin, 100 mg |
819 |
598 |
$354.37 |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
190 |
65 |
$352.98 |
| 62368 |
|
30 |
25 |
$340.24 |
| 93289 |
|
14 |
13 |
$326.52 |
| 87046 |
|
754 |
699 |
$316.59 |
| 0124A |
|
2,976 |
2,927 |
$308.55 |
| 95971 |
|
91 |
88 |
$300.67 |
| 84402 |
|
1,582 |
1,483 |
$294.20 |
| 90714 |
|
66 |
57 |
$289.25 |
| 87517 |
|
436 |
404 |
$283.02 |
| 64494 |
|
660 |
410 |
$282.56 |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
53 |
47 |
$282.09 |
| 70544 |
|
16 |
15 |
$275.52 |
| 96138 |
|
53 |
50 |
$273.61 |
| 86708 |
|
1,804 |
1,713 |
$273.08 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
826 |
732 |
$263.44 |
| 88312 |
|
717 |
643 |
$259.95 |
| 86694 |
|
367 |
250 |
$255.52 |
| J9190 |
Injection, fluorouracil, 500 mg |
720 |
338 |
$252.29 |
| 92235 |
|
29 |
24 |
$244.31 |
| 84450 |
|
1,778 |
1,639 |
$237.15 |
| 86146 |
|
183 |
167 |
$236.00 |
| Q0221 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg |
16 |
14 |
$235.30 |
| 86147 |
|
285 |
264 |
$228.86 |
| 87252 |
|
13 |
12 |
$223.24 |
| G0010 |
Administration of hepatitis b vaccine |
1,427 |
1,369 |
$222.92 |
| 84466 |
|
1,587 |
1,508 |
$222.05 |
| 80175 |
|
526 |
477 |
$220.17 |
| 72157 |
|
235 |
227 |
$220.10 |
| 82390 |
|
459 |
427 |
$217.35 |
| V2025 |
Deluxe frame |
563 |
560 |
$213.31 |
| 82140 |
|
582 |
518 |
$204.03 |
| 90474 |
|
11,136 |
10,966 |
$192.84 |
| 86431 |
|
2,694 |
2,539 |
$186.98 |
| 82810 |
|
150 |
80 |
$182.02 |
| 90632 |
|
26 |
26 |
$180.06 |
| 84590 |
|
1,131 |
1,093 |
$179.86 |
| 82248 |
|
1,155 |
869 |
$179.63 |
| 84155 |
|
1,870 |
1,571 |
$179.61 |
| 77001 |
|
204 |
178 |
$177.40 |
| 84207 |
|
444 |
424 |
$177.40 |
| 86665 |
|
247 |
174 |
$170.02 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
301 |
256 |
$167.87 |
| 87510 |
|
5,549 |
5,214 |
$161.96 |
| 84255 |
|
875 |
851 |
$154.77 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
5,975 |
5,342 |
$154.75 |
| 83021 |
|
110 |
88 |
$154.62 |
| A6258 |
Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing |
107 |
93 |
$151.05 |
| 17003 |
|
270 |
242 |
$150.90 |
| 0083A |
|
98 |
94 |
$150.28 |
| 36592 |
|
589 |
249 |
$145.82 |
| 97164 |
|
28 |
28 |
$144.41 |
| 88360 |
|
14 |
14 |
$143.07 |
| 84630 |
|
1,486 |
1,430 |
$130.30 |
| 87206 |
|
43 |
27 |
$126.94 |
| 83519 |
|
23 |
13 |
$123.54 |
| V2107 |
Spherocylinder, single vision, plus or minus 4.25 to plus or minus 7.00 sphere, .12 to 2.00d cylinder, per lens |
254 |
254 |
$121.43 |
| 82951 |
|
163 |
162 |
$120.16 |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
52 |
50 |
$118.12 |
| 90674 |
|
14 |
14 |
$117.66 |
| 91307 |
|
316 |
237 |
$116.19 |
| 20605 |
|
13 |
13 |
$115.18 |
| 76775 |
|
27 |
26 |
$114.94 |
| 0296T |
|
28 |
27 |
$113.69 |
| 82652 |
|
40 |
38 |
$110.32 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
251 |
219 |
$106.74 |
| 86036 |
|
39 |
38 |
$104.43 |
| 76377 |
|
15 |
14 |
$100.03 |
| 83002 |
|
1,516 |
1,431 |
$99.08 |
| 99454 |
|
47 |
47 |
$98.66 |
| 80179 |
|
2,156 |
1,956 |
$97.79 |
| 86787 |
|
299 |
246 |
$97.22 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
183 |
103 |
$97.00 |
| 83721 |
|
1,910 |
1,775 |
$95.96 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
137 |
133 |
$88.42 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
6,087 |
5,860 |
$86.58 |
| 84460 |
|
1,878 |
1,726 |
$84.49 |
| 83921 |
|
833 |
784 |
$76.36 |
| 86644 |
|
32 |
24 |
$71.36 |
| 86800 |
|
575 |
544 |
$70.72 |
| 77338 |
|
52 |
50 |
$68.90 |
| 86335 |
|
85 |
70 |
$60.55 |
| 82947 |
|
2,716 |
2,156 |
$59.64 |
| 82610 |
|
500 |
465 |
$58.36 |
| 83525 |
|
1,357 |
1,330 |
$58.01 |
| 90653 |
|
13 |
13 |
$57.76 |
| 62369 |
|
265 |
250 |
$55.44 |
| 83521 |
|
418 |
344 |
$53.40 |
| C1892 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away |
470 |
403 |
$53.30 |
| 86301 |
|
323 |
279 |
$46.20 |
| 86663 |
|
13 |
13 |
$45.00 |
| 72158 |
|
258 |
243 |
$40.34 |
| 86780 |
|
514 |
477 |
$38.56 |
| L0140 |
Cervical, semi-rigid, adjustable (plastic collar) |
33 |
26 |
$38.55 |
| 99408 |
|
179 |
147 |
$38.33 |
| 84480 |
|
343 |
323 |
$31.52 |
| 82945 |
|
165 |
141 |
$28.62 |
| 87116 |
|
29 |
26 |
$27.69 |
| 84157 |
|
169 |
148 |
$26.73 |
| 82365 |
|
12 |
12 |
$24.71 |
| 84481 |
|
1,081 |
1,026 |
$23.39 |
| 86880 |
|
78 |
60 |
$21.85 |
| 96417 |
|
1,966 |
1,188 |
$21.59 |
| 85613 |
|
232 |
199 |
$21.30 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
107 |
88 |
$16.60 |
| 84133 |
|
232 |
196 |
$15.17 |
| 86735 |
|
43 |
42 |
$14.50 |
| 87209 |
|
244 |
224 |
$14.38 |
| 86707 |
|
56 |
51 |
$12.85 |
| 87350 |
|
94 |
89 |
$12.81 |
| 86364 |
|
723 |
703 |
$10.76 |
| G0109 |
Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes |
53 |
49 |
$10.66 |
| 20560 |
|
468 |
366 |
$9.39 |
| 92060 |
|
44 |
42 |
$8.59 |
| 86593 |
|
521 |
500 |
$7.83 |
| 95974 |
|
45 |
42 |
$7.45 |
| 84145 |
|
216 |
169 |
$7.32 |
| 20561 |
|
566 |
393 |
$6.31 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
44 |
40 |
$5.78 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
24 |
24 |
$5.49 |
| 80235 |
|
15 |
14 |
$3.17 |
| 83930 |
|
81 |
76 |
$0.44 |
| S9455 |
Diabetic management program, group session |
104 |
98 |
$0.09 |
| 64484 |
|
92 |
89 |
$0.00 |
| V2632 |
Posterior chamber intraocular lens |
1,945 |
1,442 |
$0.00 |
| 86258 |
|
139 |
136 |
$0.00 |
| 84154 |
|
523 |
486 |
$0.00 |
| 41899 |
Unlisted procedure, dentoalveolar structures |
685 |
475 |
$0.00 |
| 84432 |
|
28 |
26 |
$0.00 |
| 86812 |
|
13 |
13 |
$0.00 |
| 74174 |
|
83 |
78 |
$0.00 |
| V2105 |
Spherocylinder, single vision, plano to plus or minus 4.00d sphere, 4.25 to 6.00d cylinder, per lens |
142 |
141 |
$0.00 |
| 20550 |
|
805 |
622 |
$0.00 |
| 64405 |
|
223 |
211 |
$0.00 |
| 64635 |
|
105 |
100 |
$0.00 |
| J9045 |
Injection, carboplatin, 50 mg |
175 |
110 |
$0.00 |
| J9267 |
Injection, paclitaxel, 1 mg |
107 |
53 |
$0.00 |
| 91065 |
|
143 |
133 |
$0.00 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
87 |
69 |
$0.00 |
| 84144 |
|
92 |
82 |
$0.00 |
| 86381 |
|
128 |
125 |
$0.00 |
| 82952 |
|
151 |
150 |
$0.00 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
167 |
145 |
$0.00 |
| 97804 |
|
68 |
68 |
$0.00 |
| 96040 |
|
191 |
184 |
$0.00 |
| 99156 |
|
80 |
70 |
$0.00 |
| 81599 |
|
12 |
12 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
75 |
63 |
$0.00 |
| 84446 |
|
49 |
49 |
$0.00 |
| 86664 |
|
41 |
40 |
$0.00 |
| 96368 |
|
111 |
85 |
$0.00 |
| 74420 |
|
124 |
103 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
106 |
89 |
$0.00 |
| 96411 |
|
154 |
96 |
$0.00 |
| 86695 |
|
76 |
71 |
$0.00 |
| 70543 |
|
13 |
12 |
$0.00 |
| 81332 |
|
13 |
12 |
$0.00 |
| 11900 |
|
77 |
74 |
$0.00 |
| 86870 |
|
126 |
104 |
$0.00 |
| 90620 |
|
14 |
14 |
$0.00 |
| 88311 |
|
96 |
77 |
$0.00 |
| 84300 |
|
120 |
112 |
$0.00 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
15 |
15 |
$0.00 |
| 96139 |
|
41 |
38 |
$0.00 |
| 86225 |
|
140 |
133 |
$0.00 |
| 73720 |
|
18 |
14 |
$0.00 |
| 86341 |
|
20 |
12 |
$0.00 |
| V2744 |
Tint, photochromatic, per lens |
13 |
13 |
$0.00 |
| 57454 |
|
69 |
66 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
46 |
40 |
$0.00 |
| 52287 |
|
29 |
25 |
$0.00 |
| C1726 |
Catheter, balloon dilatation, non-vascular |
96 |
84 |
$0.00 |
| A4615 |
Cannula, nasal |
27 |
26 |
$0.00 |
| V2755 |
U-v lens, per lens |
12 |
12 |
$0.00 |
| J3471 |
Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) |
51 |
42 |
$0.00 |
| J1097 |
Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml |
33 |
27 |
$0.00 |
| J8501 |
Aprepitant, oral, 5 mg |
14 |
12 |
$0.00 |
| 82575 |
|
14 |
12 |
$0.00 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
18 |
12 |
$0.00 |
| 87184 |
|
28 |
26 |
$0.00 |
| 88108 |
|
14 |
12 |
$0.00 |
| 82024 |
|
36 |
36 |
$0.00 |
| 76820 |
|
15 |
12 |
$0.00 |
| 77470 |
|
15 |
12 |
$0.00 |
| 97597 |
|
43 |
13 |
$0.00 |
| 82436 |
|
26 |
26 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
18 |
13 |
$0.00 |
| 87506 |
|
20 |
12 |
$0.00 |
| 64445 |
|
22 |
15 |
$0.00 |
| M0221 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
15 |
13 |
$0.00 |
| J0185 |
Injection, aprepitant, 1 mg |
24 |
15 |
$0.00 |
| 80354 |
|
340 |
286 |
$0.00 |
| J3473 |
Injection, hyaluronidase, recombinant, 1 usp unit |
252 |
216 |
$0.00 |
| 95873 |
|
723 |
642 |
$0.00 |
| 99177 |
|
798 |
787 |
$0.00 |
| 87899 |
|
374 |
360 |
$0.00 |
| J9035 |
Injection, bevacizumab, 10 mg |
91 |
72 |
$0.00 |
| 72197 |
|
102 |
97 |
$0.00 |
| 82085 |
|
55 |
53 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
291 |
223 |
$0.00 |
| C1776 |
Joint device (implantable) |
616 |
494 |
$0.00 |
| 80169 |
|
459 |
265 |
$0.00 |
| 74220 |
|
27 |
27 |
$0.00 |
| 88237 |
|
34 |
27 |
$0.00 |
| 86015 |
|
54 |
52 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
395 |
345 |
$0.00 |
| G0260 |
Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography |
12 |
12 |
$0.00 |
| 82595 |
|
12 |
12 |
$0.00 |
| 20552 |
|
58 |
53 |
$0.00 |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
21 |
13 |
$0.00 |
| J0735 |
Injection, clonidine hydrochloride, 1 mg |
58 |
50 |
$0.00 |
| 86753 |
|
220 |
212 |
$0.00 |
| J1750 |
Injection, iron dextran, 50 mg |
495 |
465 |
$0.00 |
| 84305 |
|
72 |
70 |
$0.00 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
13 |
12 |
$0.00 |
| 64636 |
|
122 |
99 |
$0.00 |
| J9206 |
Injection, irinotecan, 20 mg |
19 |
12 |
$0.00 |
| 82627 |
|
80 |
76 |
$0.00 |
| 95909 |
|
12 |
12 |
$0.00 |
| 95923 |
|
37 |
32 |
$0.00 |
| 85060 |
|
101 |
94 |
$0.00 |
| V2750 |
Anti-reflective coating, per lens |
74 |
74 |
$0.00 |
| 95921 |
|
14 |
12 |
$0.00 |
| 84166 |
|
16 |
14 |
$0.00 |
| 90681 |
|
29 |
28 |
$0.00 |
| Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
46 |
24 |
$0.00 |
| 86682 |
|
112 |
91 |
$0.00 |
| A4306 |
Disposable drug delivery system, flow rate of less than 50 ml per hour |
111 |
64 |
$0.00 |
| 62323 |
|
41 |
39 |
$0.00 |
| 91308 |
|
21 |
17 |
$0.00 |
| 95874 |
|
56 |
50 |
$0.00 |
| 86696 |
|
78 |
73 |
$0.00 |
| V2410 |
Variable asphericity lens, single vision, full field, glass or plastic, per lens |
13 |
13 |
$0.00 |
| 82042 |
|
68 |
42 |
$0.00 |
| 84681 |
|
30 |
30 |
$0.00 |
| 84445 |
|
12 |
12 |
$0.00 |
| 36600 |
|
42 |
39 |
$0.00 |
| 82747 |
|
13 |
12 |
$0.00 |
| 99157 |
|
48 |
40 |
$0.00 |
| 96549 |
|
24 |
12 |
$0.00 |
| J1095 |
Injection, dexamethasone 9 percent, intraocular, 1 microgram |
21 |
12 |
$0.00 |
| 43249 |
|
16 |
15 |
$0.00 |